Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference

Core Insights - Capricor Therapeutics announced that the results from its Phase 3 HOPE-3 clinical study of Deramiocel for Duchenne muscular dystrophy (DMD) will be presented at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference [1][2] Company Overview - Capricor Therapeutics is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, with Deramiocel as its lead product candidate for DMD [10] - The company has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency (EMA) for Deramiocel, along with Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S. and Advanced Therapy Medicinal Product (ATMP) designation in Europe [7][8] Clinical Study Details - The HOPE-3 trial is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of Deramiocel in DMD patients, involving 106 subjects [9] - The trial includes both non-ambulatory and ambulatory boys, who receive either Deramiocel or placebo every three months for a total of four doses during the first year [9] Regulatory Efforts - Capricor has submitted the clinical study report (CSR) for HOPE-3 to the FDA as part of the ongoing Biologics License Application (BLA) review process, aiming for a potential approval decision [2][3] - The CSR submission addresses items outlined in the Complete Response Letter (CRL) from the FDA and supports the ongoing review of the BLA for Deramiocel [3] Presentation Details - The late-breaking presentation at the MDA Conference is scheduled for March 11, 2026, at 2:45 p.m. ET, focusing on the musculoskeletal and cardiac benefits of Deramiocel in DMD [3]